Skip to Content

Value The Markets

Stock Market Review for the Retail Investor

Tag

Open Orphan

Open Orphan strengthens board with Elaine Sullivan hire
24 Nov 2020
Open Orphan leads weighty Wellcome Trust bid to define human challenge drug standards
19 Nov 2020
The second-gen Covid-19 stocks offering explosive opportunities
12 Nov 2020
Open Orphan lands another £2.5m flu challenge study contract
06 Nov 2020
Open Orphan extends pharmacometrics relationship with tier 1 German pharma company
30 Oct 2020
Analysis: Strong outlook for Open Orphan on UK Government contract and wider portfolio progress
28 Oct 2020
Open Orphan reveals transformational Covid-19 vaccine contract with UK government
20 Oct 2020
Open Orphan hits record highs after winning £4.3m vaccine contract
28 Sep 2020
Round-up: Busy week for Open Orphan as it pushes forward Covid and oncology arms (ORPH)
25 Sep 2020
Open Orphan courts more major pharma backing with £4m RSV contract
10 Aug 2020
Open Orphan announces major contract for Covid-19 vaccine trial (ORPH)
28 Jul 2020
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
15 Jul 2020
Open Orphan’s hVIVO expands lab growth revenue with three new contract wins (ORPH)
07 Jul 2020
Open Orphan hits accumulation stage with operational profitability slated for Q3 2020 (ORPH)
01 Jul 2020
Open Orphan signs new vaccine contract with “world leading” pharma player (ORPH)
11 Jun 2020
Open Orphan launches Covid-19 antibody test (ORPH)
04 Jun 2020
Open Orphan raises £12 million to boost Covid-19 operations (ORPH)
22 May 2020
Open Orphan share price spikes as Covid-19 home testing stocks rocket (ORPH)
18 May 2020
VIDEO: Open Orphan’s Cathal Friel on firm’s ambitious plans in the coronavirus vaccination space
13 May 2020
Open Orphan’s rapid growth continues with Covid-19 antibody test deal (ORPH)
11 May 2020
Open Orphan races ahead with £3.5m US human challenge study contract (ORPH)
04 May 2020
Open Orphan kickstarts Covid-19 test (ORPH)
23 Apr 2020
VIDEO: Open Orphan’s Cathal Friel on pharma services firm’s plans and COVID-19 work (piworld) (ORPH)
17 Mar 2020
Open Orphan one step closer to breakthrough universal flu vaccine as Phase 3 trials proceed (ORPH)
10 Mar 2020
Open Orphan’s Cathal Friel on firm’s “milestone” human coronavirus challenge study (ORPH)
09 Mar 2020
Open Orphan signs £3.2m challenge study deal with upside potential (ORPH)
06 Mar 2020
Open Orphan primed to support coronavirus vaccine work after bringing in world-leading experts (ORPH)
27 Feb 2020
Open Orphan brings in hVIVO founder Prof. John Oxford to head up coronavirus committee (ORPH)
20 Feb 2020
The Shifting Shares review of this year’s Growth and Innovation Forum (Part 2/2)
17 Feb 2020
VIDEO: Open Orphan’s Cathal Friel details ambitious 2020 plans following £5.3m raise in exclusive presentation (ORPH)
12 Feb 2020
Open Orphan expects profits within months as it plans role in coronavirus treatment (ORPH)
05 Feb 2020
Cathal Friel reiterates his full-time executive commitment to Open Orphan as hVIVO merger advances (ORPH)
06 Jan 2020
Open Orphan signs key contract with Pennsylvania’s SFA Therapeutics (ORPH)
18 Dec 2019
Open Orphan signs five clients to Genomic Health Data platform ahead of launch (ORPH)
25 Nov 2019
ValueTheMarkets Podcast 032 – with Maurice Treacy, Chief Commercial Officer of Open Orphan (ORPH)
22 Nov 2019
Open Orphan announces second deal in a week – hear more on the ValueTheMarkets podcast (ORPH)
19 Nov 2019
ValueTheMarkets Podcast 030 – with Cathal Friel, CEO of Open Orphan (ORPH)
18 Nov 2019
Open Orphan signs key agreement with major biopharma player (ORPH)
11 Nov 2019
VIDEO: Open Orphan’s Maurice Treacy details pharma services firm’s ambitious growth plans in exclusive ValueTheMarkets presentation (ORPH)
31 Oct 2019
EXCLUSIVE WEBINAR: Open Orphan to discuss its ambitious plans for high growth in the pharma services market (ORPH)
29 Oct 2019
Open Orphan – Consolidating the fragmented pharma services market (ORPH)
15 Oct 2019

teathers app screenshot

App Empowering Private Investors

Crowd Equity for Placings, IPOs and Live Market Blockbuilds, designed to give private investors access to placements and Intial Public Offerings (IPOs), predominantly on the London Stock Exchange’s Alternative Investment Market (AIM).